They do have a bit of revenue (now including any revenue from the Kaneabis side) and they are working to produce and distribute 4 OTC products which could generate big revenue, especially with an improved perception of cannabis by the general public, which they are contributing to as well with the docu (and more upcoming docus) along with many other organisations and companies.
They are also making progress in the preparation of their final FDA submission package, and there are some very good arguments to have them get fast track approval (look at the side effects of the recently approved fast track drug erivedge for skin cancer, these are all side effects on which cannabinoids work wonders, and side effects that are much more negative than any cannabis oil could have).
I don't see how you can say the technicals and fundamentals aren't there, and how this would even be all that important with 3 days of opportunity for media coverage of the docu coming up. Big news and big publicity will make the stock skyrocket on monday, and the docu will play the entire month, allowing for coverage to be spread out over this time period and maybe slowly make its way to bigger and bigger channels and newspapers.
Then there's still the fact that there is this little organisation called Green Asset International that has raised $100 million dollars of which a sizeable portion will more than likely be funded in CBIS (we have gone over the different pieces of evidence for this repeatedly in the past).
Large pharma (with a few exceptions like perhaps GW pharmaceuticals, if you can count that as large pharma) will not develop any cannabis oil medicine anytime soon as that would not suit their purpose, namely to have a gazillion different expensive synthetic products that work (usually badly) on one issue and have a gazillion side effects for which you have to take other drugs. What they are mostly doing now is putting individual, synthetically created components like THC and CBD in pills, and then seeing that they don't work all that well since the synergetic effect between the different cannabinoids and the whole array of their effects is lost.
Don't sell (all) your stock at .22-.24, you might be very disappointed afterwards.
News 
Market Data 
Discover 
AI
